HCL vs. non-HCL | Before PSM | HCL vs. non-HCL | After PSM |
|---|
HR (95% CI) | P value | HR (95% CI) | P value |
|---|
| | | | TVF | 2.10 (1.15–3.81) | 0.015 |
MACE | 1.52 (1.10–2.11) | 0.011 | MACE | 1.72 (1.01–2.94) | 0.047 |
All-cause death | 1.25 (0.73–2.16) | 0.415 | All–cause death | 1.56 (0.64–3.80) | 0.332 |
Cardiac death | 2.06 (1.04–4.05) | 0.037 | Cardiac death | 3.20 (0.86–12.00) | 0.084 |
MI | 1.33 (0.83–2.13) | 0.243 | MI | 2.19 (1.00–4.78) | 0.050 |
ARR | 2.08 (1.39–3.11) | < 0.001 | ARR | 2.20 (1.07–4.52) | 0.032 |
| | | | T/CVR | 2.29 (1.03–5.11) | 0.042 |
- The HR in the total cohort was adjusted by patient age, male, EF, eGFR, total lesion length, minimum reference vessel diameter, presentation of ACS, prior MI, current smoker, diabetes, hypertension, and dyslipidemia. To adjust the HR in the PSM cohort, the total lesion length was replaced by target/control lesion length, and multi-vessel disease was added
- ACS, acute coronary syndrome; ARR, any repeat revascularization; CI, confident interval; HCL, heavily calcified lesion; HR, hazard ratio; MACE, patient adverse event; MI, myocardial infarction; PSM, propensity score matching; ST, stent thrombosis; TVF, target lesion failure; T/CVR, target or control vessel revascularization
